Truist reiterates Amgen stock hold rating amid MariTide obesity data

Truist Securities maintained its Hold rating and $298 price target on Amgen (AMGN) following detailed Phase 2 data for its obesity drug MariTide, which showed efficacy consistent with prior reports but an adverse event profile deemed "not attractive enough to be differentiated" despite exploratory dose escalation. While Truist projects potential peak sales of $5.6 billion for MariTide, it expressed concerns regarding the drug's ability to establish a competitive profile in the increasingly crowded obesity market. Investors await further clarity from Part 2 of the Phase 2 maintenance study data, expected in the second half of 2025.

Analysis

Truist Securities has reiterated a Hold rating and a $298.00 price target on Amgen following the presentation of detailed Phase 2 data for its obesity drug, MariTide. The analysis indicates that while the drug's efficacy aligns with previously disclosed topline results, its adverse event profile is not sufficiently differentiated to provide a competitive advantage in the crowded obesity market. Despite improved tolerability shown in exploratory dose escalation analyses, Truist expresses uncertainty regarding the effectiveness of Amgen's planned dose escalation strategy for its upcoming Phase 3 trials. The firm continues to model a significant $5.6 billion in potential peak sales for MariTide, banking on Amgen's proven commercialization capabilities. However, this potential is tempered by the risk that the treatment may struggle to establish a superior profile. Investors face a prolonged period of uncertainty, as further clarifying data from the Phase 2 maintenance study is not anticipated until the second half of 2025.

Key Decisions for Investors

• Investors should recognize that MariTide's commercial success is heavily contingent on the yet-unproven ability of a Phase 3 dose escalation strategy to mitigate side effects and establish a competitive tolerability profile.
• Given the Hold rating and a $298 price target, the current risk/reward profile appears balanced, suggesting that significant upside is unlikely until further clinical data de-risks the asset in H2 2025.
• Monitor competitor advancements in the obesity drug space closely, as any new data on efficacy or safety from rivals could directly impact MariTide's projected $5.6 billion peak sales and overall market positioning.